InVivo Therapeutics Provides Enrollment Update for INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury – BioSpace

Richard Toselli, M.D., President and Chief Executive Officer of InVivo, said, We made a dedicated effort to efficiently activate strategic clinical sites during the first half of the year and are pleased with the resulting pace of enrollment to date, with our team maintaining focus on enrollment efforts and engagement at the site level. In addition, we appreciate the investigators support of this trial, which we believe has the potential to address a long unmet medical need for spinal cord injury patients.

About the INSPIRE 2.0 Study

The INSPIRE 2.0 Study is a two-arm 20-patient (10 subjects in each study arm), randomized, controlled trial designed to provide clinical data that will supplement the existing clinical results from the companys previous single-arm study (INSPIRE 1.0). The definition of study success for the INSPIRE 2.0 Study is that the difference in the proportion of subjects who demonstrate an improvement of at least one grade on ASIA Impairment Scale assessment at the six-month primary endpoint follow-up visit between the Scaffold Arm and the Comparator Arm must be equal to or greater than 20%.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Childrens Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as believe, anticipate, intend, estimate, will, may, should, expect and similar expressions, and include statements regarding the expectations related to continued updates and outcomes from the INSPIRE 2.0 Study. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Companys ability to obtain FDA approval to commercialize its products; the Companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companys products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, and its other filings with the SEC, including the Companys Form 10-K, Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005143/en/

Read more:
InVivo Therapeutics Provides Enrollment Update for INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury - BioSpace